Go Pro
→ My top 3 AI picks for the next decade (From The Oxford Club) (Ad)tc pixel
NASDAQ:DYN

Dyne Therapeutics Q2 2025 Earnings Report

Dyne Therapeutics logo
$24.95 -0.19 (-0.76%)
As of 04:00 PM Eastern
ProfileEarnings HistoryForecast

Dyne Therapeutics EPS Results

Actual EPS
-$0.97
Consensus EPS
-$0.99
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

Dyne Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Dyne Therapeutics Announcement Details

Quarter
Q2 2025
Date
7/28/2025
Time
Before Market Opens
Conference Call Date
Monday, July 28, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Dyne Therapeutics' Q3 2026 earnings is estimated for Wednesday, November 4, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, October 29, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Dyne Therapeutics' Q2 2025 Press ReleasePress Release
(8-K)
Dyne Therapeutics' Q2 2025 Quarterly reportQuarterly report
(10-Q)

Dyne Therapeutics Earnings Headlines

Dyne Therapeutics Announces Preclinical Data Supporting Four DMD Exon-Skipping Candidates Advancing Into IND-Enabling Studies
September 3 at 7:51 AM  |  quiverquant.comQ
Dyne Therapeutics to Present Preclinical Data for Multiple Development Candidates for Duchenne Muscular Dystrophy (DMD) at 27th Annual NMSG Scientific Meeting
September 3 at 7:30 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/03/3355789/0/en/dyne-therapeutics-to-present-preclinical-data-for-multiple-development-candidates-for-duchenne-muscular-dystrophy-dmd-at-27th-annual-nmsg-scientific-meeting.html
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel
September 3 at 1:00 AM  |  Chaikin Analytics (Ad)
Dyne Therapeutics to Participate in Upcoming Investor Conferences
September 2 at 7:30 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/02/3355019/0/en/dyne-therapeutics-to-participate-in-upcoming-investor-conferences.html
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 20, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/20/3348792/0/en/dyne-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html
Raymond James Reaffirms Their Buy Rating on Dyne Therapeutics (DYN)
August 6, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/DYN/pressreleases/3684969/raymond-james-reaffirms-their-buy-rating-on-dyne-therapeutics-dyn/
See More Dyne Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Dyne Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Dyne Therapeutics and other key companies, straight to your email.

About Dyne Therapeutics

Dyne Therapeutics (NASDAQ:DYN) is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells. This strategy aims to address the challenges of systemic delivery and off‐target effects that have limited prior antisense and gene therapy efforts in neuromuscular disorders. By optimizing both the ligand and the cargo, Dyne seeks to achieve sustained target engagement in affected tissues while minimizing exposure elsewhere.

Headquartered in Cambridge, Massachusetts, Dyne Therapeutics operates research and development facilities in the United States and collaborates with partners across Europe and Asia to support global clinical development. The company completed its initial public offering on the Nasdaq market in early 2021, enabling the expansion of its pipeline and investment in manufacturing capabilities for future late‐stage programs.

Dyne’s leadership team brings together executives with extensive experience in biotechnology, pharmaceutical development and clinical operations. The company is governed by a board of directors and scientific advisory members who have led successful drug development programs across multiple therapeutic areas. Dyne continues to engage with patient communities, regulatory agencies and academic institutions to advance its mission of delivering next‐generation therapies for people living with devastating neuromuscular diseases.

View Dyne Therapeutics Profile
Earnings Tools